1. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints 
Argonde C. van Harten, Pieter Jelle Visser, Yolande A.L. Pijnenburg, Charlotte E. Teunissen, Marinus A. Blankenstein, Philip Scheltens, Wiesje M. van der Flier 
Alzheimer's & Dementia: The Journal of the Alzheimer's Association 
Volume 9, Issue 5, Pages (September 2013)
DOI: /j.jalz
Copyright © 2013 The Alzheimer's Association Terms and Conditions

2. Fig. 1 Overview of patient selection.
Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2013 9, DOI: ( /j.jalz )
Copyright © 2013 The Alzheimer's Association Terms and Conditions

3. Fig. 2
Kaplan–Meier curves for Aβ42, tau, ptau and an AD biomarker profile. Kaplan–Meier curves for clinical progression with separate lines for CSF biomarker values within the reference range (uninterrupted lines) and values outside the reference range (dotted lines). Vertical lines represent censored data. The numbers entering the intervals of 0, 2, and 4 years are depicted below each figure. An AD biomarker profile was defined as: ( × tau)/Aβ42 ≥1 [18]. Log rank tests were performed to assess the difference between both lines in each plot. All differences were significant (P < .001 for Aβ42 and the AD profile, P < .01 for tau, and P < .05 for ptau).
Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2013 9, DOI: ( /j.jalz )
Copyright © 2013 The Alzheimer's Association Terms and Conditions